Eli Lilly and Company · Q2 2025
ReportedAug 7, 2025
Period endedJun 30, 2025
Rule of 40+47
The quarter in short
Revenue $15.56B, up 37.6% year over year and 22.2% on the quarter. EPS $6.29, up 91.8% year over year and 105.6% on the quarter. Free cash flow $1.39B, up 475.8% year over year and 791.0% on the quarter. Rule of 40 score +47.
Reported this quarter
Revenue
$15.56B
QoQ +22.2%
YoY +37.6%
EPS
$6.29
QoQ +105.6%
YoY +91.8%
Free Cash Flow
$1.39B
QoQ +791.0%
YoY +475.8%
Gross Margin
84.3%
QoQ +1.8 pp
YoY +3.5 pp
FCF Margin
8.9%
QoQ +7.7 pp
YoY +6.8 pp
P/E Ratio
50.7
QoQ −24.1%
YoY −54.3%
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 59478.
HTML
8-K results announcement
Filed Aug 7, 2025
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
201 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-Q quarterly report
Period ended Jun 30, 2025, filed Aug 7, 2025
ZIP
XBRL data bundle
Structured financial statements from the 10-Q
JSON
Company facts (XBRL)
Every figure LLY has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for Q2 2025, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings